S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
As a Black Woman in Business for 2 Decades, Here's How I've Learned to Navigate Microaggressions and Racism in Networking
The Safest Option in Trades! (Ad)pixel
This Is A Memorable Time To Buy Into Micron Technology
EV Battery Maker Freyr Set For Major Global Expansion
A One Stop Shop for Everything Futures Trading (Ad)pixel
Russia accused of 'kidnapping' head of Ukraine nuclear plant
How major US stock indexes fared Friday 9/30/2022
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)pixel
Putin accuses the West of sabotaging Baltic Sea pipelines
West rejects Putin's claim it sabotaged Baltic gas pipelines
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
As a Black Woman in Business for 2 Decades, Here's How I've Learned to Navigate Microaggressions and Racism in Networking
The Safest Option in Trades! (Ad)pixel
This Is A Memorable Time To Buy Into Micron Technology
EV Battery Maker Freyr Set For Major Global Expansion
A One Stop Shop for Everything Futures Trading (Ad)pixel
Russia accused of 'kidnapping' head of Ukraine nuclear plant
How major US stock indexes fared Friday 9/30/2022
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)pixel
Putin accuses the West of sabotaging Baltic Sea pipelines
West rejects Putin's claim it sabotaged Baltic gas pipelines
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
As a Black Woman in Business for 2 Decades, Here's How I've Learned to Navigate Microaggressions and Racism in Networking
The Safest Option in Trades! (Ad)pixel
This Is A Memorable Time To Buy Into Micron Technology
EV Battery Maker Freyr Set For Major Global Expansion
A One Stop Shop for Everything Futures Trading (Ad)pixel
Russia accused of 'kidnapping' head of Ukraine nuclear plant
How major US stock indexes fared Friday 9/30/2022
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)pixel
Putin accuses the West of sabotaging Baltic Sea pipelines
West rejects Putin's claim it sabotaged Baltic gas pipelines
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
As a Black Woman in Business for 2 Decades, Here's How I've Learned to Navigate Microaggressions and Racism in Networking
The Safest Option in Trades! (Ad)pixel
This Is A Memorable Time To Buy Into Micron Technology
EV Battery Maker Freyr Set For Major Global Expansion
A One Stop Shop for Everything Futures Trading (Ad)pixel
Russia accused of 'kidnapping' head of Ukraine nuclear plant
How major US stock indexes fared Friday 9/30/2022
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)pixel
Putin accuses the West of sabotaging Baltic Sea pipelines
West rejects Putin's claim it sabotaged Baltic gas pipelines
NASDAQ:SELB

Selecta Biosciences - SELB Stock Forecast, Price & News

$1.64
+0.03 (+1.86%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.59
$1.75
50-Day Range
$1.50
$2.60
52-Week Range
$0.65
$4.51
Volume
724,826 shs
Average Volume
834,847 shs
Market Capitalization
$250.44 million
P/E Ratio
164.00
Dividend Yield
N/A
Price Target
$5.33

Selecta Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
225.2% Upside
$5.33 Price Target
Short Interest
Bearish
5.61% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.71
Upright™ Environmental Score
News Sentiment
1.92mentions of Selecta Biosciences in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$4,469 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From $0.22 to ($0.42) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.29 out of 5 stars

Medical Sector

481st out of 1,093 stocks

Pharmaceutical Preparations Industry

221st out of 547 stocks

SELB stock logo

About Selecta Biosciences (NASDAQ:SELB) Stock

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising SEL-313, a product candidate in preclinical stage to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to evaluate the appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and products for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat primary biliary cholangitis and other autoimmune diseases. The company has license and collaboration agreements with Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum; Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Ginkgo Bioworks Holdings, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.

Receive SELB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Selecta Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SELB Stock News Headlines

Expert Ratings for Selecta Biosciences
See More Headlines
Receive SELB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Selecta Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SELB Company Calendar

Last Earnings
8/04/2022
Today
10/01/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SELB
Employees
58
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.33
High Stock Price Forecast
$7.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+225.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-25,690,000.00
Pretax Margin
37.36%

Debt

Sales & Book Value

Annual Sales
$85.08 million
Book Value
$0.19 per share

Miscellaneous

Free Float
106,136,000
Market Cap
$250.44 million
Optionable
Optionable
Beta
0.96

Key Executives

  • Dr. Carsten Brunn Ph.D. (Age 51)
    CEO, Pres & Director
    Comp: $883.08k
  • Ms. Ann K. Donohue CPA (Age 40)
    VP of Fin. & Controller
    Comp: $286.97k
  • Mr. Kevin TanMr. Kevin Tan (Age 45)
    Chief Financial Officer
    Comp: $515.14k
  • Dr. Lloyd Johnston Ph.D. (Age 54)
    COO and Sr. VP of R&D
    Comp: $564.12k
  • Dr. Takashi Kei Kishimoto Ph.D. (Age 62)
    Chief Scientific Officer
    Comp: $565.95k
  • Dr. Peter G. Traber M.D.Dr. Peter G. Traber M.D. (Age 67)
    Chief Medical Officer
    Comp: $642.56k
  • Dr. Ulrich H. von Andrian-Werburg M.D.
    Ph.D., Co-Founder and Co-Chair of the Scientific Advisory Board
  • Mr. Matthew Bartholomae
    Gen. Counsel & Sec.
  • Ms. Kristen Baldwin
    Chief People Officer













SELB Stock - Frequently Asked Questions

Should I buy or sell Selecta Biosciences stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Selecta Biosciences in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SELB shares.
View SELB analyst ratings
or view top-rated stocks.

What is Selecta Biosciences' stock price forecast for 2022?

3 Wall Street analysts have issued 1-year price objectives for Selecta Biosciences' stock. Their SELB share price forecasts range from $4.00 to $7.00. On average, they expect the company's share price to reach $5.33 in the next twelve months. This suggests a possible upside of 225.2% from the stock's current price.
View analysts price targets for SELB
or view top-rated stocks among Wall Street analysts.

How have SELB shares performed in 2022?

Selecta Biosciences' stock was trading at $3.26 at the beginning of the year. Since then, SELB shares have decreased by 49.7% and is now trading at $1.64.
View the best growth stocks for 2022 here
.

When is Selecta Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our SELB earnings forecast
.

How were Selecta Biosciences' earnings last quarter?

Selecta Biosciences, Inc. (NASDAQ:SELB) announced its earnings results on Thursday, August, 4th. The company reported $0.06 EPS for the quarter, topping analysts' consensus estimates of ($0.03) by $0.09. The business earned $39.27 million during the quarter, compared to the consensus estimate of $21.45 million. Selecta Biosciences had a net margin of 24.85% and a trailing twelve-month return on equity of 11.30%. During the same period in the prior year, the business posted ($0.04) earnings per share.

What other stocks do shareholders of Selecta Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Selecta Biosciences investors own include Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Rigel Pharmaceuticals (RIGL), Novavax (NVAX), Dynavax Technologies (DVAX), Geron (GERN), Catalyst Pharmaceuticals (CPRX) and TherapeuticsMD (TXMD).

When did Selecta Biosciences IPO?

(SELB) raised $64 million in an initial public offering on Wednesday, June 22nd 2016. The company issued 4,300,000 shares at $14.00-$16.00 per share. UBS Investment Bank and Stifel served as the underwriters for the IPO and Canaccord Genuity and Needham & Company were co-managers.

What is Selecta Biosciences' stock symbol?

Selecta Biosciences trades on the NASDAQ under the ticker symbol "SELB."

How do I buy shares of Selecta Biosciences?

Shares of SELB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Selecta Biosciences' stock price today?

One share of SELB stock can currently be purchased for approximately $1.64.

How much money does Selecta Biosciences make?

Selecta Biosciences (NASDAQ:SELB) has a market capitalization of $250.45 million and generates $85.08 million in revenue each year. The company earns $-25,690,000.00 in net income (profit) each year or $0.01 on an earnings per share basis.

How can I contact Selecta Biosciences?

Selecta Biosciences' mailing address is 65 Grove Street, Watertown MA, 02472. The official website for the company is selectabio.com. The company can be reached via phone at (617) 923-1400, via email at lstern@soleburytrout.com, or via fax at 617-924-3454.

This page (NASDAQ:SELB) was last updated on 10/1/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.